JP2015028034A5 - - Google Patents
Info
- Publication number
- JP2015028034A5 JP2015028034A5 JP2014174796A JP2014174796A JP2015028034A5 JP 2015028034 A5 JP2015028034 A5 JP 2015028034A5 JP 2014174796 A JP2014174796 A JP 2014174796A JP 2014174796 A JP2014174796 A JP 2014174796A JP 2015028034 A5 JP2015028034 A5 JP 2015028034A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- cancer
- acid sequence
- metastasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000539 amino acid group Chemical group 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 206010027476 Metastases Diseases 0.000 claims 12
- 230000009400 cancer invasion Effects 0.000 claims 12
- 230000009401 metastasis Effects 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 10
- 229940121647 egfr inhibitor Drugs 0.000 claims 9
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 230000004927 fusion Effects 0.000 claims 7
- 241000282412 Homo Species 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims 5
- 208000029742 colonic neoplasm Diseases 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 201000000849 skin cancer Diseases 0.000 claims 5
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 4
- 210000000170 cell membrane Anatomy 0.000 claims 4
- 229920002521 macromolecule Polymers 0.000 claims 4
- 230000005012 migration Effects 0.000 claims 4
- 238000013508 migration Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 230000026683 transduction Effects 0.000 claims 4
- 238000010361 transduction Methods 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 229960001433 erlotinib Drugs 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229940043355 kinase inhibitor Drugs 0.000 claims 3
- 229960001972 panitumumab Drugs 0.000 claims 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000015735 Beta-catenin Human genes 0.000 claims 2
- 108060000903 Beta-catenin Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 206010072082 Environmental exposure Diseases 0.000 claims 1
- 206010073310 Occupational exposures Diseases 0.000 claims 1
- 231100000675 occupational exposure Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3002108P | 2008-02-20 | 2008-02-20 | |
| US61/030,021 | 2008-02-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547751A Division JP2011512415A (ja) | 2008-02-20 | 2009-02-19 | 癌の治療および予防のための治療用ペプチドの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015028034A JP2015028034A (ja) | 2015-02-12 |
| JP2015028034A5 true JP2015028034A5 (enExample) | 2015-03-26 |
Family
ID=40848240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547751A Pending JP2011512415A (ja) | 2008-02-20 | 2009-02-19 | 癌の治療および予防のための治療用ペプチドの使用 |
| JP2014174796A Pending JP2015028034A (ja) | 2008-02-20 | 2014-08-29 | 癌の治療および予防のための治療用ペプチドの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547751A Pending JP2011512415A (ja) | 2008-02-20 | 2009-02-19 | 癌の治療および予防のための治療用ペプチドの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110014195A1 (enExample) |
| EP (1) | EP2247301B1 (enExample) |
| JP (2) | JP2011512415A (enExample) |
| CN (1) | CN101977623A (enExample) |
| AU (1) | AU2009215503B2 (enExample) |
| CA (1) | CA2714939A1 (enExample) |
| ES (1) | ES2500640T3 (enExample) |
| WO (1) | WO2009105557A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2627674A4 (en) | 2010-10-12 | 2014-04-30 | Arizona Biomedical Res Commission | EGFR BASED PEPTIDES |
| WO2016161440A2 (en) | 2015-04-03 | 2016-10-06 | Arizona Cancer Therapeutics, Llc | Egfr-based inhibitor peptides for combinatorial inactivation of erbb1, erbb2, and erbb3 |
| CN110305209B (zh) * | 2019-07-09 | 2022-09-13 | 福建医科大学附属第一医院 | 用于治疗恶性肿瘤的多肽及其作为疫苗的用途 |
| WO2022173917A1 (en) * | 2021-02-11 | 2022-08-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating breast cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1958642A1 (en) * | 2000-12-22 | 2008-08-20 | Dana-Farber Cancer Institute | Regulation of cell growth by MUC1 |
| WO2004092339A2 (en) * | 2003-04-11 | 2004-10-28 | Ilex Products, Inc. | Modulation of muc1 mediated signal transduction |
| US8129506B2 (en) * | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| RU2402569C2 (ru) * | 2004-03-19 | 2010-10-27 | Имклоун Элэлси | Человеческие антитела к рецептору эпидермального фактора роста |
| DE602005023488D1 (de) * | 2004-06-17 | 2010-10-21 | Mannkind Corp | Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie |
| CN101232895B (zh) * | 2005-04-15 | 2014-06-04 | 亚利桑那癌症治疗公司 | 用于治疗转移性癌症的治疗肽 |
-
2009
- 2009-02-19 CA CA2714939A patent/CA2714939A1/en not_active Abandoned
- 2009-02-19 WO PCT/US2009/034541 patent/WO2009105557A1/en not_active Ceased
- 2009-02-19 EP EP09712807.8A patent/EP2247301B1/en not_active Not-in-force
- 2009-02-19 ES ES09712807.8T patent/ES2500640T3/es active Active
- 2009-02-19 US US12/867,396 patent/US20110014195A1/en not_active Abandoned
- 2009-02-19 JP JP2010547751A patent/JP2011512415A/ja active Pending
- 2009-02-19 AU AU2009215503A patent/AU2009215503B2/en not_active Ceased
- 2009-02-19 CN CN2009801096259A patent/CN101977623A/zh active Pending
-
2014
- 2014-08-29 JP JP2014174796A patent/JP2015028034A/ja active Pending
-
2015
- 2015-09-09 US US14/849,402 patent/US20160082082A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123385T1 (el) | Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης | |
| PH12020551317A1 (en) | Anti-cd73 antibodies and methods of use thereof | |
| PH12018501250A1 (en) | Chimeric factor viii polypeptides and uses thereof | |
| BRPI0813898A2 (pt) | métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira. | |
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX389878B (es) | Proteinas quimericas de factor viii y usos de estas. | |
| MX350962B (es) | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. | |
| NZ731571A (en) | T cell receptors | |
| PH12019500609B1 (en) | Cd123 binding proteins and related compositions and methods | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| CA2868121C (en) | Anti-mesothelin chimeric antigen receptors | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| WO2016094873A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods | |
| EA201792485A2 (ru) | Комплекс фактора viii с xten и белком-фактором фон виллебранда и его применение (варианты) | |
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| MX2015015361A (es) | Peptidos que tienen actividad de inhibicion de infecciones de virus respiratorios, uso de los mismos y metodos de preparacion de los mismos. | |
| WO2017015630A3 (en) | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| MX2018005399A (es) | Nuevo polipeptido con afinidad por pd-l1. | |
| JP2017514522A5 (enExample) | ||
| CY1123336T1 (el) | Βελτιωμενη εκφραση ανασυνδυασμενης πρωτεϊνης χρησιμοποιωντας υβριδιο υποκινητη chef1 | |
| JP2015028034A5 (enExample) | ||
| PE20181956A1 (es) | Polipeptidos que inhiben cd40l | |
| HK1215441A1 (zh) | 人血清白蛋白结合化合物及其融合蛋白 |